Pular para o conteúdo principal

ETHNOS_APP

Início • Busca • Periódicos • Lista 0

Philip Bruggmann

Dados Biográficos

ID7446476
NOMEPhilip Bruggmann
PRENOMESPhilip
SOBRENOMEBruggmann
ASSINATURABRUGGMANN P
AFILIAÇÕESAddiction Switzerland
ORCID0000-0002-0436-8895
VERIFICADOSim
TOTAL DE OBRAS18
TOTAL DE CITAÇÕES0
TOTAL COMO AUTOR18
TOTAL COMO EDITOR0
PRIMEIRO ANO DE PUBLICAÇÃO2008
ANO MAIS RECENTE DE PUBLICAÇÃO2023
ÍNDICE H0
  • Recommandations pour la prise en charge de l’infection par le virus de l’hépatite C chez les usagers de drogues par injection

    Open Access•J Grebely, Geert Robaeys et al.•ARTICLE•International Journal of Drug…•2023

  • Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden

    Open Access•J Grebely, Geert Robaeys et al.•ARTICLE•International Journal of Drug…•2023

  • Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral

    Open Access•J Grebely, Geert Robaeys et al.•ARTICLE•International Journal of Drug…•2023

  • Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, Switzerland

    Open Access•Luis Falcato, Claudia Bernardini et al.•ARTICLE•International Journal of Drug…•2021

  • Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy

    Open Access•J Grebely, Brian Conway et al.•ARTICLE•International Journal of Drug…•2018

  • Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment

    Open Access•Nathalie Scherz, Philip Bruggmann et al.•ARTICLE•International Journal of Drug…•2018

  • Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use

    Open Access•Evan B Cunningham, Janaki Amin et al.•ARTICLE•International Journal of Drug…•2018

  • Global prevalence and genotype distribution of hepatitis C virus infection in 2015

    Open Access•Sarah Blach, Stefan Zeuzem et al.•ARTICLE•The Lancet Gastroenterology &…•2017

  • Elimination of hepatitis C virus infection among PWID

    Open Access•J Grebely, Julie Bruneau et al.•ARTICLE•International Journal of Drug…•2017

  • Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection

    Open Access•J Grebely, Olav Dalgard et al.•ARTICLE•International Journal of Drug…•2017

  • Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs

    Open Access•Håvard Midgard, Behzad Hajarizadeh et al.•ARTICLE•International Journal of Drug…•2017

  • Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs

    Open Access•J Grebely, Julie Bruneau et al.•ARTICLE•International Journal of Drug…•2017

  • Recommendations for the management of hepatitis C virus infection among people who inject drugs

    Open Access•J Grebely, Geert Robaeys et al.•ARTICLE•International Journal of Drug…•2015

  • Prevention, treatment and care of hepatitis C virus infection among people who inject drugs

    Open Access•Philip Bruggmann, J Grebely•ARTICLE•International Journal of Drug…•2015

    People who inject drugs (PWID) represent the core of the hepatitis C virus (HCV) epidemic in many countries. HCV transmission continues among PWID, despite evidence demonstrating that high coverage of combined harm reduction strategies, such as needle syringe programs (NSP) and opioid substitution treatment (OST), can be effective in reducing the risk of HCV transmission. Among infected individuals, HCV-related morbidity and mortality continues t…

  • Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs

    Open Access•J Grebely, Philip Bruggmann et al.•ARTICLE•International Journal of Drug…•2015

  • Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs

    Open Access•J Grebely, Philip Bruggmann et al.•ARTICLE•International Journal of Drug…•2015

  • Prevalence of hepatitis C in a Swiss sample of men who have sex with men

    Open Access•Alvin J Schmidt, Axel J Schmidt et al.•ARTICLE•BMC Public Health•2014

    Our findings suggest that in Switzerland, hepatitis C among MSM without diagnosed HIV is not more prevalent than in the general population. We found no evidence of elevated rates of sexual transmission of HCV among MSM without HIV-infection. Therefore, we currently see no reason for promoting HCV-testing among all MSM in Switzerland

  • An integrated model of care to counter high incidence of HIV and sexually transmitted diseases in men who have sex with men – initial analysis of service utilizers in Zurich

    Open Access•David Schwappach, David LB Schwappach et al.•ARTICLE•BMC Public Health•2008

    Since its first months of activity, the service achieved high levels of recognition, acceptance and demand in the MSM community. Contrary to common concepts of "testing clinics", the Checkpoint service provides post-exposure prophylaxis, HIV and STI treatment, psychological support and counselling and general medical care. It thus follows a holistic approach to health in the MSM community with the particular aim to serve as a "door opener" betwee…

Sem obras proeminentes nesta página.

  • An integrated model of care to counter high incidence of HIV and sexually transmitted diseases in men who have sex with men – initial analysis of service utilizers in Zurich

    Open Access•David Schwappach, David LB Schwappach et al.•ARTICLE•BMC Public Health•2008

    Since its first months of activity, the service achieved high levels of recognition, acceptance and demand in the MSM community. Contrary to common concepts of "testing clinics", the Checkpoint service provides post-exposure prophylaxis, HIV and STI treatment, psychological support and counselling and general medical care. It thus follows a holistic approach to health in the MSM community with the particular aim to serve as a "door opener" betwee…

  • Prevalence of hepatitis C in a Swiss sample of men who have sex with men

    Open Access•Alvin J Schmidt, Axel J Schmidt et al.•ARTICLE•BMC Public Health•2014

    Our findings suggest that in Switzerland, hepatitis C among MSM without diagnosed HIV is not more prevalent than in the general population. We found no evidence of elevated rates of sexual transmission of HCV among MSM without HIV-infection. Therefore, we currently see no reason for promoting HCV-testing among all MSM in Switzerland

  • Recommendations for the management of hepatitis C virus infection among people who inject drugs

    Open Access•J Grebely, Geert Robaeys et al.•ARTICLE•International Journal of Drug…•2015

  • Prevention, treatment and care of hepatitis C virus infection among people who inject drugs

    Open Access•Philip Bruggmann, J Grebely•ARTICLE•International Journal of Drug…•2015

    People who inject drugs (PWID) represent the core of the hepatitis C virus (HCV) epidemic in many countries. HCV transmission continues among PWID, despite evidence demonstrating that high coverage of combined harm reduction strategies, such as needle syringe programs (NSP) and opioid substitution treatment (OST), can be effective in reducing the risk of HCV transmission. Among infected individuals, HCV-related morbidity and mortality continues t…

  • Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs

    Open Access•J Grebely, Philip Bruggmann et al.•ARTICLE•International Journal of Drug…•2015

  • Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs

    Open Access•J Grebely, Philip Bruggmann et al.•ARTICLE•International Journal of Drug…•2015

  • Global prevalence and genotype distribution of hepatitis C virus infection in 2015

    Open Access•Sarah Blach, Stefan Zeuzem et al.•ARTICLE•The Lancet Gastroenterology &…•2017

  • Elimination of hepatitis C virus infection among PWID

    Open Access•J Grebely, Julie Bruneau et al.•ARTICLE•International Journal of Drug…•2017

  • Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection

    Open Access•J Grebely, Olav Dalgard et al.•ARTICLE•International Journal of Drug…•2017

  • Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs

    Open Access•Håvard Midgard, Behzad Hajarizadeh et al.•ARTICLE•International Journal of Drug…•2017

  • Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs

    Open Access•J Grebely, Julie Bruneau et al.•ARTICLE•International Journal of Drug…•2017

  • Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy

    Open Access•J Grebely, Brian Conway et al.•ARTICLE•International Journal of Drug…•2018

  • Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment

    Open Access•Nathalie Scherz, Philip Bruggmann et al.•ARTICLE•International Journal of Drug…•2018

  • Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use

    Open Access•Evan B Cunningham, Janaki Amin et al.•ARTICLE•International Journal of Drug…•2018

  • Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, Switzerland

    Open Access•Luis Falcato, Claudia Bernardini et al.•ARTICLE•International Journal of Drug…•2021

  • Recommandations pour la prise en charge de l’infection par le virus de l’hépatite C chez les usagers de drogues par injection

    Open Access•J Grebely, Geert Robaeys et al.•ARTICLE•International Journal of Drug…•2023

  • Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden

    Open Access•J Grebely, Geert Robaeys et al.•ARTICLE•International Journal of Drug…•2023

  • Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral

    Open Access•J Grebely, Geert Robaeys et al.•ARTICLE•International Journal of Drug…•2023

Medicine (18 obras) · Hepatitis C virus research (17 obras) · Hepatitis C virus (13 obras) · Virus (13 obras) · Hepatitis C (12 obras) · Internal Medicine (12 obras) · HIV, Drug Use, Sexual Risk (10 obras) · Immunology (10 obras) · Hepatitis B Virus Studies (8 obras) · Liver Disease Diagnosis and Treatment (6 obras)

Ethnos_APP • Projeto Open Source • Licença MIT • Frontend v2.0.0 • Privacidade e Cookies • Documentação da API: api.ethnos.app/docs • Código da API: GitHub • DOI: 10.5281/zenodo.17049435 • Código do Frontend: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae